Vetoquinol SA
PAR:VETO

Watchlist Manager
Vetoquinol SA Logo
Vetoquinol SA
PAR:VETO
Watchlist
Price: 79.3 EUR 1.28% Market Closed
Market Cap: 938.2m EUR
Have any thoughts about
Vetoquinol SA?
Write Note

Vetoquinol SA
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vetoquinol SA
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Vetoquinol SA
PAR:VETO
Interest Income Expense
€3.6m
CAGR 3-Years
N/A
CAGR 5-Years
96%
CAGR 10-Years
14%
Sanofi SA
PAR:SAN
Interest Income Expense
-€425m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ipsen SA
PAR:IPN
Interest Income Expense
-€12.7m
CAGR 3-Years
17%
CAGR 5-Years
2%
CAGR 10-Years
-25%
Virbac SA
PAR:VIRP
Interest Income Expense
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boiron SA
PAR:BOI
Interest Income Expense
€3.8m
CAGR 3-Years
N/A
CAGR 5-Years
51%
CAGR 10-Years
25%
Medincell SA
PAR:MEDCL
Interest Income Expense
-€4m
CAGR 3-Years
-5%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
No Stocks Found

Vetoquinol SA
Glance View

Market Cap
938.4m EUR
Industry
Pharmaceuticals

Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.

VETO Intrinsic Value
86.78 EUR
Undervaluation 9%
Intrinsic Value
Price

See Also

What is Vetoquinol SA's Interest Income Expense?
Interest Income Expense
3.6m EUR

Based on the financial report for Jun 30, 2024, Vetoquinol SA's Interest Income Expense amounts to 3.6m EUR.

What is Vetoquinol SA's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
14%

Over the last year, the Interest Income Expense growth was 322%.

Back to Top